Navigation Links
Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
Date:7/9/2012

PITTSBURGH, July 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded President Obama's signing of the "Food and Drug Administration Safety and Innovation Act," landmark legislation that will significantly enhance the safety and security of the U.S. drug supply chain, level the playing field to hold all drug manufacturers to FDA's inspection standards and improve timely access to high quality, affordable generic drugs.  

Mylan CEO Heather Bresch commented, "Mylan has long been a passionate leader and advocate for many of the key provisions included in this important piece of legislation that will help enhance our nation's drug supply chain, and we applaud the extraordinary efforts of the many in Congress who helped craft and pass this vital law in a bipartisan fashion. We believe these important updates to the 1938 law governing FDA will help to protect the health and safety of consumers by globalizing the reach of FDA to reflect today's global pharmaceutical supply chain and ensuring that all drug manufacturing facilities that supply the U.S. market are regularly inspected, regardless of whether they are based inside the U.S. or outside our borders. In particular, I am proud that the generics industry, through the landmark Generic Drug User Fee Act, has stepped up to the plate to help address an industry wide issue by providing FDA with approximately $1.5 billion over five years in order to help fund these increased inspections of drug facilities and ensure faster and more predictable review of generic drug applications."

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Thiamine Hydrochloride Injection
2. Mylan Launches Generic Version of Lipitor®
3. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
4. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
5. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
6. Mylan Launches Generic Version of Viramune® Tablets
7. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
8. Mylan Launches Generic Version of Plavix® Tablets
9. Mylan Launches Generic Lipitor® in Five European Countries
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... 23, 2017 The key factors driving ... diabetic population, accelerating economic growth and increasing healthcare expenditure. Some ... higher life expectancy of ESRD patients, rising demand for home ... the expansion of the market is hindered by high treatment ... ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):